DAIICHI SANKYO CO., LTD. |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 4,766 JPY | +0.78% |
|
+7.27% | +23.09% |
| 02:21pm | Scholz pledges further support for the pharmaceutical industry | DP |
| 12:55pm | Daiichi Sankyo's Attributable Profit Soars 84% in Fiscal 2024 | MT |
| Sales 2024 | 1,602B 10.29B | Sales 2025 * | 1,747B 11.23B | Capitalization | 9,068B 58.27B |
|---|---|---|---|---|---|
| Net income 2024 | 201B 1.29B | Net income 2025 * | 181B 1.16B | EV / Sales 2024 | 5.72 x |
| Net cash position 2024 * | 556B 3.57B | Net cash position 2025 * | 599B 3.85B | EV / Sales 2025 * | 4.85 x |
| P/E ratio 2024 * |
54.2
x | P/E ratio 2025 * |
50.4
x | Employees | 17,435 |
| Yield 2024 * |
0.96% | Yield 2025 * |
1.1% | Free-Float | 97.04% |
More Fundamentals
* Assessed data
More news
Latest transcript on Daiichi Sankyo Co., Ltd.
More recommendations
More press releases
More news
| 1 day | +0.78% | ||
| 1 week | +5.07% | ||
| Current month | -0.23% | ||
| 1 month | -1.16% | ||
| 3 months | +10.84% | ||
| 6 months | +16.64% | ||
| Current year | +23.09% |
1 week
4 521.00
4 977.00
1 month
4 443.004 979.00
Current year
3 847.005 173.00
1 year
3 566.005 173.00
3 years
1 981.005 173.00
5 years
1 731.005 173.00
10 years
518.675 173.00
| Managers | Title | Age | Since |
|---|---|---|---|
Sunao Manabe
CEO | Chief Executive Officer | 69 | 07-03-31 |
Hiroyuki Okuzawa
PSD | President | 61 | 17-03-31 |
Ken Takeshita
CTO | Chief Tech/Sci/R&D Officer | - | 21-03-31 |
| Members of the board | Title | Age | Since |
|---|---|---|---|
Sawako Nohara
BRD | Director/Board Member | 66 | 19-05-31 |
Kazuaki Kama
BRD | Director/Board Member | 75 | 19-05-31 |
Sunao Manabe
CEO | Chief Executive Officer | 69 | 07-03-31 |
| Name | Weight | AuM | 1st Jan change | Investor Rating |
|---|---|---|---|---|
| 25.16% | 15 M€ | +5.53% | ||
| 4.18% | 251 M€ | +13.17% | ||
| 3.32% | 174 M€ | -.--% | - | |
| 3.32% | 51 M€ | -.--% | - | |
| 3.24% | 15 M€ | +13.28% |
| Date | Price | Change | Volume |
|---|---|---|---|
| 24-04-25 | 4,766 | +0.78% | 8 225 700 |
| 24-04-24 | 4,729 | +1.42% | 4,048,900 |
| 24-04-23 | 4,663 | +0.65% | 3,096,100 |
| 24-04-22 | 4,633 | -0.06% | 3,202,900 |
| 24-04-19 | 4,636 | +2.20% | 5,970,000 |
Delayed Quote Japan Exchange, April 25, 2024 at 02:00 am EDT
More quotes
Daiichi Sankyo Company specializes in developing, manufacturing and marketing pharmaceutical products. Net sales break down by activity as follows:
- sale of medicines (99.8%): prescription medicines (92.8% of net sales) and OTC medicines (7.2%) primarily for the treatment of thrombotic disorders, tumors, diabetes and rheumatoid arthritis;
- other (0.2%): primarily real estate activities.
Net sales are distributed geographically as follows: Japan (64.1%), North America (17.2%), Europe (9.7%) and other (9%).
Sector
Pharmaceuticals
Calendar
2024-04-24
- Q4 2023 Earnings Release
Related indices
Trading Rating
Investor Rating
ESG Refinitiv
A-
Sell
Buy
Mean consensus
BUY
Number of Analysts
15
Last Close Price
4,729
JPY
Average target price
5,620
JPY
Spread / Average Target
+18.84%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| +23.09% | 58.47B | |
| +25.61% | 660B | |
| +22.73% | 562B | |
| -5.24% | 358B | |
| +16.49% | 322B | |
| +8.28% | 297B | |
| +12.42% | 219B | |
| -10.02% | 196B | |
| +6.36% | 199B | |
| -8.75% | 149B |
- Stock Market
- Equities
- 4568 Stock
